Sobi files oral Orfadin in Europe
This article was originally published in Scrip
Executive Summary
An application by Swedish Orphan Biovitrum (Sobi) for an oral suspension of Orfadin (nitisinone) has been accepted by the European Medicines Agency (EMA). The new dosage form is aimed at making the administration of Orfadin, currently formulated as a hard capsule, easier and more accurate.